Effectiveness of Cladribine vs Fingolimod, Natalizumab, Ocrelizumab, and Alemtuzumab in Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Mult. Scler. 2024 Aug 01;[EPub Ahead of Print], I Roos, S Sharmin, C Malpas, S Ozakbas, J Lechner-Scott, S Hodgkinson, R Alroughani, S Eichau Madueño, C Boz, A van der Walt, H Butzkueven, K Buzzard, O Skibina, M Foschi, F Grand'Maison, N John, P Grammond, M Terzi, J Prévost, M Barnett, G Laureys, L Van Hijfte, J Luis Sanchez-Menoyo, Y Blanco, J Oh, P McCombe, C Ramo Tello, A Soysal, A Prat, P Duquette, BI Yamout, S Khoury, V van Pesch, R Macdonell, M José Sá, M Slee, J Kuhle, D Maimone, D Spitaleri, B Willekens, AA Asmi, E Tallantyre, NP Robertson, A Coles, JW L Brown, T KalincikFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.